WHO WE ARE

INEX Innovate is Asia's first
molecular diagnostics company for women

INEX Innovate is constantly innovating to address valuable clinical unmet needs with diagnostic test offerings, and has developed a broad range of IP.

EXPANSION

Strategic expansion into growing markets

DEVELOPMENT

Development of robust
product pipeline

INNOVATION

Commitment to excellence in laboratory practice

OUR FOCUS

Improving women’s health through

innovative diagnostics

epiHERA™ is a Minimally Invasive Early Endometrial Cancer Detection Test

CORO® Real-Time RT-PCR SARS-CoV-2 kit

OvaCis® accurately discriminates benign from malignant epithelial ovarian cysts in 15 minutes

epiDX® is a blood-based test for the early diagnosis of breast cancer

LEXI® is a patented methodology of the isolation of fetal cells in maternal blood

XENA® is an early detection blood test for ovarian cancer.

Our commitment to
innovation

INEX is dedicated to applying our R&D and proven commercial capabilities to address unmet needs in women’s and fetal health.
We develop solutions to some of the most prevalent women’s health challenges whilst ensuring equity and access to products.
FIND OUT MORE
INNOVATION
PROGRESS
SYNERGY
IP
67
PARTNERSHIPS
25
TEAM
53
ONGOING PROJECTS
4
THE DIFFERENCE

We are a research-driven company with focus on developing diagnostics platforms based on hard science. We work to deliver value to the most important stakeholder — the patient.

PARTNER WITH US
MAKING STRIDES

Global Footprint

Singapore
USA
China
United Kingdom
Hong Kong
Indonesia
India
Bangladesh
Myanmar
Malaysia
Thailand
INSIGHTS

Latest news

Announcements

Last week iGene Laboratory hosted two CME events titled “Changes In The Maternal and Fetal Health Landscape” at 1880 Singapore and the Grand Hyatt Jakarta.

Announcements

INEX Innovate is pleased to announce the acceptance of it’s scientific paper titled “Validation of epiHERA®, a minimally invasive PCR tool for hypermethylated CD01/CELF4 genes associated with endometrial cancer” for presentation at the Association for Molecular Pathology (AMP) Congress 2023 in Milan IT.

Announcements

INEX Innovate delighted to announce the appointment of Biomed Global as distributor for the launch of OvaCis® – The Company’s Test for Ovarian Cancer in Indonesia, Malaysia, Philippines, Singapore and Thailand.

Announcements

iGene Laboratory announces the launch of Whole Exome Sequencing with it’s FetalExome test service as covered by biomedical publication BioSpectrum Asia today.